Future FinTech Signs Framework Agreement to Acquire TransGen SC Tech Limited Expanding into the Biomedical R&D Sector

Core Viewpoint - Future FinTech is expanding into the biomedical sector by acquiring TransGen SC Tech Limited, which specializes in biofactor research and development, particularly in treatments for diabetes and Alzheimer's disease [1][3][7]. Acquisition Details - Future FinTech's subsidiary, FTFT HK, signed a Framework Agreement for the acquisition of 100% of TransGen's shares, expected to be completed within 90 days, pending due diligence and financial audit [1][2]. - A formal acquisition agreement will follow a satisfactory outcome of the due diligence process [2]. TransGen's Capabilities - TransGen focuses on biofactor R&D, utilizing naturally occurring compounds for health promotion and disease prevention [3]. - The company conducts advanced research on microalgal extracellular vesicles, which are used for targeted drug delivery and diagnostics [4]. - TransGen holds 26 invention and utility model patents, along with certifications such as the Level 2 Biosafety Laboratory Certification and the Human Umbilical Cord Mesenchymal Stem Cells Qualification Certificate [4][5]. Industry Standards and Leadership - TransGen has contributed to the formulation of industry standards for mesenchymal stem cells, highlighting its technological capabilities and leadership in the biomedical field [6]. Strategic Implications - The acquisition aligns with Future FinTech's strategy to diversify into the biomedical sector, leveraging its fintech capabilities to create innovative funding vehicles for medical initiatives [7]. - The partnership is expected to enhance TransGen's international expansion and promote the industrialization of its technologies, providing long-term value for shareholders [7].